ST Renfu announced that Hubei Biomedical Industry Technology Research Institute Co., Ltd., a wholly-owned subsidiary of the company, recently received the HW281171 “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration and agreed to carry out clinical trials. This drug is a new chemical class 1 oral small molecule drug intended for the treatment of chronic urticaria. Currently, there are no drugs with the same target and indications on the market in China, and 2 companies have already entered phase I clinical stage. Up to now, the project has invested about 30 million yuan in R&D. Subsequent companies will begin work related to clinical research. There is uncertainty about drug development and marketing. Investors are kindly requested to pay attention to investment risks.

Zhitongcaijing · 2d ago
ST Renfu announced that Hubei Biomedical Industry Technology Research Institute Co., Ltd., a wholly-owned subsidiary of the company, recently received the HW281171 “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration and agreed to carry out clinical trials. This drug is a new chemical class 1 oral small molecule drug intended for the treatment of chronic urticaria. Currently, there are no drugs with the same target and indications on the market in China, and 2 companies have already entered phase I clinical stage. Up to now, the project has invested about 30 million yuan in R&D. Subsequent companies will begin work related to clinical research. There is uncertainty about drug development and marketing. Investors are kindly requested to pay attention to investment risks.